Soft­Bank leads $150M round in­to Dew­point as con­den­sate biotech nears clin­ic

In an­oth­er mar­ket, Dew­point Ther­a­peu­tics may have gone pub­lic about now and raised a prince­ly sum.

Al­though they’re still around two years from hu­man tri­als, the biotech al­ready has blue-chip VC back­ers, three Big Phar­ma part­ner­ships, and a com­pelling sto­ry about be­ing the first and biggest en­trant to a new field of bi­ol­o­gy. But Wall Street isn’t buy­ing much of any­thing these days.

So Dew­point will have to set­tle for the next best thing: a ven­ture cap­i­tal firm that of­ten acts as if it has as much mon­ey as Wall Street — Soft­Bank.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER